Full Breakdown
AstraZeneca Halts volrustomig Lung Cancer Trial After Unfavorable Interim Results
8/17/2026, 8:14:17 PM
Trial Termination Details
On August 17, 2026, AstraZeneca announced the discontinuation of the Phase III eVOLVE-Lung02 trial, which evaluated the bispecific antibody volrustomig with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC) with PD-L1 < 50 %. An Independent Data Monitoring Committee (IDMC) reviewed interim data and concluded that the regimen was unlikely to meet either of the dual primary endpoints—progression-free survival (PFS) or overall survival (OS)—in the primary analysis population (PD-L1 < 1 %). The safety profile remained consistent with known profiles of the individual agents, with no new safety signals.
Background on volrustomig and Trial Design
Volrustomig is a dual checkpoint inhibitor bispecific antibody that blocks PD-1 and CTLA-4 on the same T cell. The open-label, randomized trial enrolled 895 patients across 25 countries. The experimental arm paired volrustomig with standard chemotherapy; the control arm used pembrolizumab (Keytruda) plus chemotherapy. The study targeted patients with lower PD-L1 expression, a group that typically shows less durable responses to existing immunotherapies.
Data & Statistics
- Enrollment: 895 patients, 25 countries.
- Primary analysis population: PD-L1 < 1 % (dual primary endpoints: PFS, OS).
- Secondary analysis: Intent-to-treat population with PD-L1 < 50 %.
- Commercial impact: The halted trial represented roughly 20 % of volrustomig’s peak-sales estimate, previously projected at over $5 billion.
Official Statements & Responses
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, said the company is “disappointed” but will learn from the outcome and continue pursuing new lung-cancer medicines. AstraZeneca pledged to work with investigators to ensure continuity of care for participants and confirmed that other Phase III volrustomig studies in cervical cancer, head-and-neck squamous-cell carcinoma, and mesothelioma will proceed. The company reaffirmed its July forecasts, including a target of $80 billion in annual revenue by 2030, and highlighted recent positive readouts from separate lung-cancer trials.
Parallel Positive Oncology Updates
In the same announcement cycle, AstraZeneca reported that the Phase III SAFFRON trial of Tagrisso (osimertinib) plus Orpathys (savolitinib) met its primary and key secondary endpoints, showing statistically significant improvements in both PFS and OS for EGFR-mutated NSCLC with MET-driven resistance. The company also disclosed encouraging results for the Enhertu antibody-drug conjugate in NSCLC, underscoring a mixed clinical picture for its oncology pipeline.
Why It Matters
The discontinuation highlights the difficulty of developing effective immunotherapies for patients with low PD-L1 expression, a sizable subset of lung-cancer deaths. While investor confidence has been tested by recent trial setbacks, the continuation of other volrustomig programs and the success of Tagrisso-Orpathys suggest AstraZeneca’s broader pipeline remains a focal point for future growth.
Conflicting Reports & Gaps
Source descriptions of the control arm differ: Reuters identifies Merck’s Keytruda plus chemotherapy, while AstraZeneca’s release cites pembrolizumab plus chemotherapy. No detailed efficacy data for the volrustomig arm were disclosed, leaving the magnitude of the shortfall against primary endpoints unspecified.
Verbatim Quote
- “While we are disappointed, we will learn from this trial,” — Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca
